Aug 29, 2018
iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update
Jul 16, 2018
iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials – Phase 1 Oral Amphotericin B

View All News (+)

Enter Your Email to Sign Up for
iCo Therapeutics Updates

About iCo Therapeutics

iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus areas and if so the Company will seek to capture further value via partnerships, such as its partnership with Immune Pharmaceuticals (NASDAQ: IMNP), which is in several Phase 2 studies involving iCo-008. iCo shares trade on the TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”.

Copyright 2015 ICO Therapeutics | Disclaimer